Transdermal Estradiol with Micronized Progesterone: Optimal Hormone Therapy for Perimenopause – RCT
Year: 2025
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: This randomized controlled trial evaluated the efficacy and safety of various hormone replacement therapy (HRT) regimens in 840 perimenopausal women aged 45-55 years. Participants were allocated to receive either transdermal 17β-estradiol with micronized progesterone, oral conjugated estrogens with medroxyprogesterone acetate, transdermal estradiol with dydrogesterone, or non-hormonal therapy for 24 months. Vasomotor symptom reduction was the main result, with safety profiles, metabolic paramete
DOI: 10.51847/7eoq7of0w6
Institution: Stavropol State Medical University
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4412781875